Get the Stockscreener App
58.53
3.94%
2.22
After Hours:
58.09
-0.44
-0.75%
Royalty Pharma Plc stock is traded at $58.53, with a volume of 3.60M.
It is up +3.94% in the last 24 hours and up +7.97% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$56.31
Open:
$56.67
24h Volume:
3.60M
Relative Volume:
1.00
Market Cap:
$25.94B
Revenue:
$2.44B
Net Income/Loss:
$1.36B
P/E Ratio:
30.66
EPS:
1.9093
Net Cash Flow:
$574.14M
1W Performance:
+0.98%
1M Performance:
+7.97%
6M Performance:
+47.99%
1Y Performance:
+64.41%
1-Day Range:
$56.45
$58.60
1-Week Range:
$54.95
$58.60
52-Week Range:
$34.08
$58.84
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
58.53 | 24.96B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 121.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
678.94 | 69.66B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
857.97 | 53.99B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
179.18 | 39.21B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
283.15 | 37.27B | 4.29B | 577.22M | 641.34M | 4.2086 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
RPHC5824522 Bond Coupon Profile — Rate & Payments - TradingView
Royalty Pharma to announce Q2 2026 financial results on August 5 - scanx.trade
Royalty Pharma schedules 8 a.m. webcast for Aug. 5 results - Stock Titan
US78081BAN3 Bond Coupon Profile — Rate & Payments - TradingView
US78081BAN3 Bond Risk Profile - TradingView
Royalty Pharma PLC $RPRX Shares Sold by J. Safra Sarasin Holding AG - MarketBeat
Calamos Advisors LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
RPHC5824522 Bond Risk Profile - TradingView
RPHC5824522 Bond Profile — Key Metrics - TradingView
Calamos Wealth Management LLC Acquires New Shares in Royalty Pharma PLC $RPRX - MarketBeat
US78081BAQ6 Bond Coupon Profile — Rate & Payments - TradingView
Canal Insurance CO Acquires Shares of 20,000 Royalty Pharma PLC $RPRX - MarketBeat
RPHC5237891 Bond Profile — Key Metrics - TradingView
RPHC5237891 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5237891 Bond Risk Profile - TradingView
US78081BAQ6 Bond Risk Profile - TradingView
US78081BAQ6 Bond Profile — Key Metrics - TradingView
Royalty Pharma (RPRX) Stock Analysis: A Strategic Look At Growth And Valuation Potential - DirectorsTalk Interviews
Royalty Pharma Q1 2026 earnings preview - MSN
World Investment Advisors Sells 48,485 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX is Torray Investment Partners LLC's Largest Position - MarketBeat
Hsbc Holdings PLC Lowers Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Morgan Stanley’s 22nd Annual Global Healthcare Conference summary - Quartr
Royalty Pharma (RPRX) Citi Annual Global Healthcare Conference 2025 Summary - Quartr
Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again - Yahoo! Finance Canada
Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choice - Yahoo! Finance Canada
Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Russell 1000 Defensive Inclusion Might Change The Case For Investing In Royalty Pharma (RPRX) - Sahm
How (RPRX) Movements Inform Risk Allocation Models - Stock Traders Daily
RPRX or ACAD: Which Is the Better Value Stock Right Now? - Yahoo Finance
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial - Sahm
Royalty Pharma (RPRX) Could Be 2% Undervalued On Russell 1000 Defensive Index Addition - Sahm
Y Intercept Hong Kong Ltd Grows Stake in Royalty Pharma PLC $RPRX - MarketBeat
Swedbank AB Sells 355,450 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma stock hits all-time high at 58.02 USD By Investing.com - Investing.com South Africa
Royalty Pharma stock hits all-time high at 58.02 USD - Investing.com
Royalty Pharma plc (RPRX) Stock Analysis: Navigating the Biotech Sector with Robust Revenue Growth - DirectorsTalk Interviews
Royalty Pharma PLC $RPRX Shares Sold by Inspire Investing LLC - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Boosts Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Fideuram Intesa Sanpaolo Private Banking S.P.A. Has $439,000 Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Moran Wealth Management LLC Boosts Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ETFs Investing in Royalty Pharma Plc Class A Stocks - TradingView
USS Investment Management Ltd Boosts Position in Royalty Pharma PLC $RPRX - MarketBeat
Pictet Asset Management Holding SA Increases Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Sells $5,652,000.00 in Stock - MarketBeat
[Form 4] Royalty Pharma plc Insider Trading Activity - Stock Titan
Royalty Pharma (RPRX) EVP Hite sells 130,000 shares in 10b5-1 trades - Stock Titan
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 9,099 Shares - MarketBeat
Royalty Pharma plc (RPRX) insider Marshall Urist reports sales totaling ~$1.95M - Stock Titan
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
7.51%
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):